This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Interventions
The three interventions were hepatic resection followed by salvage OLT, locoregional therapy followed by salvage OLT, and primary OLT.
Location/setting
USA/hospital.
Methods

Analytical approach:
The analysis was based on a Markov model, with a 10-year time horizon. The authors stated that it was carried out from a societal perspective.
Effectiveness data:
The clinical inputs were from a critical review of the literature on hepatocellular carcinoma in the PubMed database. Reviews or meta-analyses were selected, if available, otherwise randomised controlled trials or prospective studies were selected. Some assumptions were made. Five-year survival was a key input and was from the selected studies.
Monetary benefit and utility valuations:
The utility values for the health states were from the literature.
Measure of benefit:
Quality-adjusted life-years (QALYs) were the summary benefit measure and they were discounted at an annual rate of 3%.
Cost data:
The economic analysis included the costs of the treatments, long-term care, and compensated cirrhosis. These estimates were from published studies of institutional costs and studies in which Medicare or similar data were used. All costs
